- Home
- CHN vs KLRS Comparison
CHN vs KLRS Comparison
Compare CHN & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHN
- KLRS
- Stock Information
- Founded
- CHN 1992
- KLRS 2019
- Country
- CHN United States
- KLRS United States
- Employees
- CHN N/A
- KLRS N/A
- Industry
- CHN Investment Managers
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CHN Finance
- KLRS Health Care
- Exchange
- CHN Nasdaq
- KLRS Nasdaq
- Market Cap
- CHN 128.4M
- KLRS 129.0M
- IPO Year
- CHN N/A
- KLRS N/A
- Fundamental
- Price
- CHN $13.07
- KLRS $2.40
- Analyst Decision
- CHN
- KLRS Buy
- Analyst Count
- CHN 0
- KLRS 1
- Target Price
- CHN N/A
- KLRS N/A
- AVG Volume (30 Days)
- CHN 31.8K
- KLRS 46.4K
- Earning Date
- CHN 01-01-0001
- KLRS 08-15-2025
- Dividend Yield
- CHN 0.19%
- KLRS N/A
- EPS Growth
- CHN N/A
- KLRS N/A
- EPS
- CHN N/A
- KLRS N/A
- Revenue
- CHN N/A
- KLRS N/A
- Revenue This Year
- CHN N/A
- KLRS N/A
- Revenue Next Year
- CHN N/A
- KLRS N/A
- P/E Ratio
- CHN N/A
- KLRS N/A
- Revenue Growth
- CHN N/A
- KLRS N/A
- 52 Week Low
- CHN $9.00
- KLRS $2.38
- 52 Week High
- CHN $12.98
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- CHN 58.19
- KLRS N/A
- Support Level
- CHN $13.13
- KLRS N/A
- Resistance Level
- CHN $13.33
- KLRS N/A
- Average True Range (ATR)
- CHN 0.17
- KLRS 0.00
- MACD
- CHN 0.01
- KLRS 0.00
- Stochastic Oscillator
- CHN 75.70
- KLRS 0.00
About CHN China Fund Inc. (The)
CHINA FUND INC is a non-diversified, closed-end management investment company. Its investment objective is a long-term capital appreciation which it seeks to achieve by investing in equity securities with trading in China and outside China. It invests in various industries such as Insurance, Entertainment, Machinery, Electrical Equipment, Beverages, Hotels, Restaurants, and Leisure among others.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.